Equasens (FR:EQS)
:EQS
Top Page
Equasens
(EQS)
Select Model
Select Model
Rating:64Neutral
Price Target:
€43.00
▲(2.63% Upside)
Action:ReiteratedDate:11/07/25
Equasens receives an overall stock score of 64, driven primarily by mixed financial performance (score: 67, weight: 50%) with a strong balance sheet offset by declining profitability and cash flow concerns. Valuation (score: 70, weight: 20%) provides a positive contribution with a reasonable P/E ratio and attractive dividend yield, while technical analysis (score: 55, weight: 30%) indicates caution due to a bearish price trend. The score reflects a stable but cautious outlook for the stock.
Positive Factors
Business Model Strength
Equasens' diverse revenue streams from subscriptions and device sales provide a stable and recurring income base, enhancing financial resilience.
Negative Factors
Revenue Growth Challenges
The recent dip in revenue growth may indicate challenges in market expansion or product adoption, impacting long-term growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Business Model Strength
Equasens' diverse revenue streams from subscriptions and device sales provide a stable and recurring income base, enhancing financial resilience.
Read all positive factors
Equasens (EQS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€602.32M
Dividend Yield2.85%
Average Volume (3M)10.91K
Price to Earnings (P/E)8.1
Beta (1Y)0.63
Revenue Growth4.45%
EPS Growth-14.08%
CountryFR
Employees1,271
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)1.44
Shares Outstanding15,174,125
10 Day Avg. Volume9,833
30 Day Avg. Volume10,915
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)2.90
Price to Sales (P/S)3.10
P/FCF Ratio18.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.13
Revenue Forecast (FY)€261.52M
Equasens Business Overview & Revenue Model
Company Description
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, ...
How the Company Makes Money
Equasens generates revenue through multiple streams, including subscription fees for its software platforms, licensing agreements for its proprietary technology, and consulting services tailored to healthcare institutions. The company also benefit...
Equasens Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
75
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 224.81M | 216.80M | 219.79M | 214.07M | 193.07M | 171.75M |
| Gross Profit | 40.63M | 47.13M | 69.88M | 145.52M | 133.82M | 119.31M |
| EBITDA | 53.65M | 62.99M | 71.30M | 67.36M | 63.77M | 55.53M |
| Net Income | 37.15M | 36.20M | 47.05M | 46.38M | 39.12M | 30.71M |
Balance Sheet | ||||||
| Total Assets | 410.92M | 398.01M | 394.05M | 350.81M | 329.95M | 295.78M |
| Cash, Cash Equivalents and Short-Term Investments | 81.73M | 40.16M | 54.69M | 68.01M | 64.79M | 63.28M |
| Total Debt | 49.13M | 48.45M | 69.27M | 66.52M | 84.06M | 71.81M |
| Total Liabilities | 171.66M | 157.32M | 166.42M | 154.01M | 164.72M | 146.82M |
| Stockholders Equity | 229.97M | 231.51M | 219.28M | 189.78M | 159.00M | 143.26M |
Cash Flow | ||||||
| Free Cash Flow | 50.88M | 35.91M | 43.17M | 46.75M | 37.09M | 27.53M |
| Operating Cash Flow | 53.39M | 47.55M | 61.59M | 56.98M | 47.52M | 47.21M |
| Investing Cash Flow | -19.88M | -13.90M | -50.53M | -18.34M | -36.19M | -39.14M |
| Financing Cash Flow | -40.92M | -36.20M | -16.09M | -39.88M | -9.80M | 4.16M |
Equasens Technical Analysis
Positive
41.90
Price Trends
36.61
Positive
39.55
Positive
42.34
Negative
Market Momentum
0.96
Negative
63.30
Neutral
83.14
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EQS, the sentiment is Positive. The current price of 41.9 is above the 20-day moving average (MA) of 36.71, above the 50-day MA of 36.61, and below the 200-day MA of 42.34, indicating a neutral trend. The MACD of 0.96 indicates Negative momentum. The RSI at 63.30 is Neutral, neither overbought nor oversold. The STOCH value of 83.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:EQS.
Equasens Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | €602.32M | 8.13 | 16.40% | 2.85% | 4.45% | -14.08% | |
60 Neutral | €173.48M | 17.85 | -5.44% | ― | 3.79% | -797.10% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | €162.16M | -0.80 | 59.08% | ― | 6.75% | 15.48% | |
42 Neutral | €240.13M | 26.96 | 1.32% | ― | 12.47% | -65.87% |
* General Sector Average
FR:EQS
Equasens
40.05
3.85
10.63%
FR:ALCGM
Cegedim
12.20
0.55
4.72%
FR:ALERS
Eurobio-Scientific SA
24.00
-0.25
-1.05%
FR:ALMDT
Median Technologies
4.41
1.83
70.74%
FR:ALBIO
Biosynex SA
0.85
-0.55
-39.29%
FR:ABLD
ABL Diagnostics SA
2.84
-2.66
-48.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.